| 1 | incident | 3,031 |
| 2 | alcoholic | 1,084 |
| 3 | new-onset | 909 |
| 4 | early-onset | 525 |
| 5 | drug-resistant | 511 |
| 6 | late-onset | 383 |
| 7 | insulin-dependent | 313 |
| 8 | non-insulin-dependent | 283 |
| 9 | type-2 | 270 |
| 10 | senile | 249 |
| 11 | type-1 | 210 |
| 12 | screen-detected | 200 |
| 13 | recent-onset | 157 |
| 14 | cholestatic | 156 |
| 15 | frank | 138 |
| 16 | streptozotocin-induced | 115 |
| 17 | adult-onset | 110 |
| 18 | stz-induced | 100 |
| 19 | post-cabg | 94 |
| 20 | pregestational | 72 |
| 21 | childhood-onset | 69 |
| 22 | hbv-related | 60 |
| 23 | newly-diagnosed | 59 |
| 24 | hcv-related | 57 |
| 25 | steroid-induced | 54 |
| 26 | drug-refractory | 53 |
| 27 | type-ii | 48 |
| 28 | drug-sensitive | 47 |
| 29 | alloxan-induced | 46 |
| 30 | nephrogenic | 37 |
| 31 | noninsulin-dependent | 34 |
| 32 | non-b | 33 |
| 33 | drug-susceptible | 29 |
| 34 | ebv-positive | 29 |
| 35 | lamivudine-resistant | 26 |
| 36 | juvenile-onset | 25 |
| 37 | pre-gestational | 25 |
| 38 | maturity-onset | 23 |
| 39 | insulin-requiring | 21 |
| 40 | hospital-treated | 18 |
| 41 | non-ulcerative | 18 |
| 42 | amebic | 17 |
| 43 | multi-infarct | 16 |
| 44 | non-proteinuric | 16 |
| 45 | nonresistant | 15 |
| 46 | all-type | 14 |
| 47 | evidence.• | 13 |
| 48 | noncarcinogenic | 13 |
| 49 | well-compensated | 13 |
| 50 | early-course | 12 |
| 51 | center-involved | 11 |
| 52 | igm-mgus | 11 |
| 53 | posthepatitic | 11 |
| 54 | young-onset | 11 |
| 55 | ectoparasitic | 10 |
| 56 | less-controlled | 10 |
| 57 | mmr-deficient | 10 |
| 58 | presenile | 10 |
| 59 | thiazide-induced | 10 |
| 60 | hnf1a | 9 |
| 61 | type1 | 9 |
| 62 | type2 | 9 |
| 63 | biopsy-negative | 8 |
| 64 | center-involving | 8 |
| 65 | hcv-induced | 8 |
| 66 | pipkin | 8 |
| 67 | later-onset | 7 |
| 68 | non-f | 7 |
| 69 | noninsulin-treated | 7 |
| 70 | rsv-associated | 7 |
| 71 | ssc-associated | 7 |
| 72 | treatment-failure | 7 |
| 73 | arteritic | 6 |
| 74 | class1 | 6 |
| 75 | gestational-onset | 6 |
| 76 | hepatitis-related | 6 |
| 77 | high-mic | 6 |
| 78 | serious/severe | 6 |
| 79 | youth-onset | 6 |
| 80 | non-c | 5 |
| 81 | non-cavitary | 5 |
| 82 | non-intervened | 5 |
| 83 | pre-senile | 5 |
| 84 | ypt0-2 | 5 |
| 85 | ch-fed | 4 |
| 86 | ebv-negative | 4 |
| 87 | fomepizole-treated | 4 |
| 88 | g2/g3 | 4 |
| 89 | genotype-3 | 4 |
| 90 | hepatogenous | 4 |
| 91 | jo2-induced | 4 |
| 92 | non-biliogenic | 4 |
| 93 | non-reentrant | 4 |
| 94 | overseas-acquired | 4 |
| 95 | pancreatogenic | 4 |
| 96 | poorly-controlled | 4 |
| 97 | post-hepatectomy | 4 |
| 98 | post-vitrectomy | 4 |
| 99 | vh-derived | 4 |
| 100 | 1,420 | 3 |
| 101 | 9340 | 3 |
| 102 | acute/early | 3 |
| 103 | alloxan-treated | 3 |
| 104 | clinically-suspected | 3 |
| 105 | glp-treated | 3 |
| 106 | halogen-substituted | 3 |
| 107 | insulinopenic | 3 |
| 108 | isoniazid-associated | 3 |
| 109 | nafld-associated | 3 |
| 110 | noninsulin-requiring | 3 |
| 111 | nonneovascular | 3 |
| 112 | pre-ascitic | 3 |
| 113 | pseudo-resistant | 3 |
| 114 | streptozocin-induced | 3 |
| 115 | travel-associated | 3 |
| 116 | tubotympanic | 3 |
| 117 | well-healed | 3 |
| 118 | 13,102 | 2 |
| 119 | 3,430 | 2 |
| 120 | 5647 | 2 |
| 121 | 6214 | 2 |
| 122 | bilineal | 2 |
| 123 | cancer-unaffected | 2 |
| 124 | co-managing | 2 |
| 125 | crown-group | 2 |
| 126 | crt-d-treated | 2 |
| 127 | daily-wear | 2 |
| 128 | de-compensated | 2 |
| 129 | h-resistant | 2 |
| 130 | heat-shock-treated | 2 |
| 131 | high/elevated | 2 |
| 132 | holter-detected | 2 |
| 133 | kazal | 2 |
| 134 | laser-refractory | 2 |
| 135 | low-substituted | 2 |
| 136 | lvd-resistant | 2 |
| 137 | medemine | 2 |
| 138 | moderate-to-high-risk | 2 |
| 139 | nathanson | 2 |
| 140 | nkt-cell-dependent | 2 |
| 141 | non-gbs | 2 |
| 142 | non-hemiplegic | 2 |
| 143 | non-mho | 2 |
| 144 | non-nodule | 2 |
| 145 | nonparanoid | 2 |
| 146 | pi-resistant | 2 |
| 147 | postcabg | 2 |
| 148 | postpancreatitis | 2 |
| 149 | prism-based | 2 |
| 150 | revascularizable | 2 |
| 151 | schistosoma-infected | 2 |
| 152 | stz-na-induced | 2 |
| 153 | subcompensated | 2 |
| 154 | taintless | 2 |
| 155 | vtec-associated | 2 |
| 156 | xdr-pulmonary | 2 |
| 157 | 'breakfast | 1 |
| 158 | 1,744,659 | 1 |
| 159 | 10,722 | 1 |
| 160 | 117,000 | 1 |
| 161 | 12,835 | 1 |
| 162 | 14,806 | 1 |
| 163 | 15,859 | 1 |
| 164 | 150,389 | 1 |
| 165 | 16,254 | 1 |
| 166 | 17,213 | 1 |
| 167 | 19,864 | 1 |
| 168 | 19,909 | 1 |
| 169 | 20,586 | 1 |
| 170 | 24,937 | 1 |
| 171 | 25,759 | 1 |
| 172 | 27884=cect | 1 |
| 173 | 285.4 | 1 |
| 174 | 29,452 | 1 |
| 175 | 3,492 | 1 |
| 176 | 3,548 | 1 |
| 177 | 3,748 | 1 |
| 178 | 36,600 | 1 |
| 179 | 37,514 | 1 |
| 180 | 4,606 | 1 |
| 181 | 4-n-alkylamino-substituted | 1 |
| 182 | 49/592 | 1 |
| 183 | 4932 | 1 |
| 184 | 5,009 | 1 |
| 185 | 5,076 | 1 |
| 186 | 504,844 | 1 |
| 187 | 58,162 | 1 |
| 188 | 58/61 | 1 |
| 189 | 5811 | 1 |
| 190 | 620,478 | 1 |
| 191 | 7,252 | 1 |
| 192 | 7,490 | 1 |
| 193 | 8,226 | 1 |
| 194 | 816,149 | 1 |
| 195 | 86,075 | 1 |
| 196 | 8d3 | 1 |
| 197 | 9,710 | 1 |
| 198 | 94256 | 1 |
| 199 | 962-1757 | 1 |
| 200 | 97,854 | 1 |
| 201 | all+ | 1 |
| 202 | all++ | 1 |
| 203 | all+++ | 1 |
| 204 | amelorating | 1 |
| 205 | an-restricting | 1 |
| 206 | atheroma-related | 1 |
| 207 | bari-eligible | 1 |
| 208 | benfluorex-induced | 1 |
| 209 | bionator-treated | 1 |
| 210 | biopsy-documented | 1 |
| 211 | bone/skin | 1 |
| 212 | bpiv3-associated | 1 |
| 213 | burnt-out | 1 |
| 214 | carcinogens-chronic | 1 |
| 215 | central-involved | 1 |
| 216 | challenge-proved | 1 |
| 217 | ciprofloxacin-imipenem-trimethoprim/sulfamethoxazole-resistant | 1 |
| 218 | drug-resistant-mtb | 1 |
| 219 | dual-graft | 1 |
| 220 | efthidermum | 1 |
| 221 | ethnically-homogeneous | 1 |
| 222 | food-poisoning | 1 |
| 223 | ginseng-treated | 1 |
| 224 | glucose-defined | 1 |
| 225 | haemolysis-elevated | 1 |
| 226 | hba1c-defined | 1 |
| 227 | hepatotoxin-induced | 1 |
| 228 | hirame | 1 |
| 229 | histopathology-verified | 1 |
| 230 | hoki | 1 |
| 231 | htt-treated | 1 |
| 232 | incident/recurrent | 1 |
| 233 | indoline-2,3-diones | 1 |
| 234 | influenza-negative | 1 |
| 235 | insulin-dependand | 1 |
| 236 | intertsil | 1 |
| 237 | interval-cancer | 1 |
| 238 | isio-4-fed | 1 |
| 239 | laparoscopically-proven | 1 |
| 240 | lewy-body | 1 |
| 241 | lipoatrophy-associated | 1 |
| 242 | literacy-tailored | 1 |
| 243 | low-mic | 1 |
| 244 | lower-specificity | 1 |
| 245 | mat-adjacent | 1 |
| 246 | mci/mild | 1 |
| 247 | medically-diagnosed | 1 |
| 248 | melancholic/non-melancholic | 1 |
| 249 | mets/no | 1 |
| 250 | mg/dl/no | 1 |
| 251 | miiand | 1 |
| 252 | modified-process | 1 |
| 253 | msa-cerebellar | 1 |
| 254 | newonset | 1 |
| 255 | nm-absorbing | 1 |
| 256 | non-fatal/fatal | 1 |
| 257 | non-i/r | 1 |
| 258 | non-insulin-dependence | 1 |
| 259 | nonnephropathic | 1 |
| 260 | nonsalvageable | 1 |
| 261 | nsclc-mediated | 1 |
| 262 | numeracy-focused | 1 |
| 263 | numeracy-sensitive | 1 |
| 264 | nurse/certified | 1 |
| 265 | obese- | 1 |
| 266 | officially-certified | 1 |
| 267 | one-hundred-eight | 1 |
| 268 | organically-based | 1 |
| 269 | participants.computer-based | 1 |
| 270 | pioglitazone-for | 1 |
| 271 | plaque-negative | 1 |
| 272 | plc-associated | 1 |
| 273 | post-ctr | 1 |
| 274 | post-pneumonic | 1 |
| 275 | postmenopausal-elderly | 1 |
| 276 | preretinopathic | 1 |
| 277 | proinflammatory/anti-inflammatory | 1 |
| 278 | ptz-and | 1 |
| 279 | quebracho/kg | 1 |
| 280 | re-creating | 1 |
| 281 | restrictive-purging | 1 |
| 282 | ruboxistaurin-treated | 1 |
| 283 | sagb-alone | 1 |
| 284 | serially-admitted | 1 |
| 285 | sham-smt/control | 1 |
| 286 | siuds/sids | 1 |
| 287 | spermatozoa-positive | 1 |
| 288 | stat3-wild | 1 |
| 289 | streptozotocin-nicotinamide-induced | 1 |
| 290 | streptozotocininduced | 1 |
| 291 | sub-optimally-controlled | 1 |
| 292 | supracardiac | 1 |
| 293 | trational | 1 |
| 294 | trimesters.median | 1 |
| 295 | tus-measured | 1 |
| 296 | uti,4 | 1 |
| 297 | vascugel-treated | 1 |
| 298 | weeks.serum | 1 |
| 1 | 'breakfast | 1 |
| 2 | 1,420 | 3 |
| 3 | 1,744,659 | 1 |
| 4 | 10,722 | 1 |
| 5 | 117,000 | 1 |
| 6 | 12,835 | 1 |
| 7 | 13,102 | 2 |
| 8 | 14,806 | 1 |
| 9 | 15,859 | 1 |
| 10 | 150,389 | 1 |
| 11 | 16,254 | 1 |
| 12 | 17,213 | 1 |
| 13 | 19,864 | 1 |
| 14 | 19,909 | 1 |
| 15 | 20,586 | 1 |
| 16 | 24,937 | 1 |
| 17 | 25,759 | 1 |
| 18 | 27884=cect | 1 |
| 19 | 285.4 | 1 |
| 20 | 29,452 | 1 |
| 21 | 3,430 | 2 |
| 22 | 3,492 | 1 |
| 23 | 3,548 | 1 |
| 24 | 3,748 | 1 |
| 25 | 36,600 | 1 |
| 26 | 37,514 | 1 |
| 27 | 4,606 | 1 |
| 28 | 4-n-alkylamino-substituted | 1 |
| 29 | 49/592 | 1 |
| 30 | 4932 | 1 |
| 31 | 5,009 | 1 |
| 32 | 5,076 | 1 |
| 33 | 504,844 | 1 |
| 34 | 5647 | 2 |
| 35 | 58,162 | 1 |
| 36 | 58/61 | 1 |
| 37 | 5811 | 1 |
| 38 | 620,478 | 1 |
| 39 | 6214 | 2 |
| 40 | 7,252 | 1 |
| 41 | 7,490 | 1 |
| 42 | 8,226 | 1 |
| 43 | 816,149 | 1 |
| 44 | 86,075 | 1 |
| 45 | 8d3 | 1 |
| 46 | 9,710 | 1 |
| 47 | 9340 | 3 |
| 48 | 94256 | 1 |
| 49 | 962-1757 | 1 |
| 50 | 97,854 | 1 |
| 51 | acute/early | 3 |
| 52 | adult-onset | 110 |
| 53 | alcoholic | 1,084 |
| 54 | all+ | 1 |
| 55 | all++ | 1 |
| 56 | all+++ | 1 |
| 57 | all-type | 14 |
| 58 | alloxan-induced | 46 |
| 59 | alloxan-treated | 3 |
| 60 | amebic | 17 |
| 61 | amelorating | 1 |
| 62 | an-restricting | 1 |
| 63 | arteritic | 6 |
| 64 | atheroma-related | 1 |
| 65 | bari-eligible | 1 |
| 66 | benfluorex-induced | 1 |
| 67 | bilineal | 2 |
| 68 | bionator-treated | 1 |
| 69 | biopsy-documented | 1 |
| 70 | biopsy-negative | 8 |
| 71 | bone/skin | 1 |
| 72 | bpiv3-associated | 1 |
| 73 | burnt-out | 1 |
| 74 | cancer-unaffected | 2 |
| 75 | carcinogens-chronic | 1 |
| 76 | center-involved | 11 |
| 77 | center-involving | 8 |
| 78 | central-involved | 1 |
| 79 | ch-fed | 4 |
| 80 | challenge-proved | 1 |
| 81 | childhood-onset | 69 |
| 82 | cholestatic | 156 |
| 83 | ciprofloxacin-imipenem-trimethoprim/sulfamethoxazole-resistant | 1 |
| 84 | class1 | 6 |
| 85 | clinically-suspected | 3 |
| 86 | co-managing | 2 |
| 87 | crown-group | 2 |
| 88 | crt-d-treated | 2 |
| 89 | daily-wear | 2 |
| 90 | de-compensated | 2 |
| 91 | drug-refractory | 53 |
| 92 | drug-resistant | 511 |
| 93 | drug-resistant-mtb | 1 |
| 94 | drug-sensitive | 47 |
| 95 | drug-susceptible | 29 |
| 96 | dual-graft | 1 |
| 97 | early-course | 12 |
| 98 | early-onset | 525 |
| 99 | ebv-negative | 4 |
| 100 | ebv-positive | 29 |
| 101 | ectoparasitic | 10 |
| 102 | efthidermum | 1 |
| 103 | ethnically-homogeneous | 1 |
| 104 | evidence.• | 13 |
| 105 | fomepizole-treated | 4 |
| 106 | food-poisoning | 1 |
| 107 | frank | 138 |
| 108 | g2/g3 | 4 |
| 109 | genotype-3 | 4 |
| 110 | gestational-onset | 6 |
| 111 | ginseng-treated | 1 |
| 112 | glp-treated | 3 |
| 113 | glucose-defined | 1 |
| 114 | h-resistant | 2 |
| 115 | haemolysis-elevated | 1 |
| 116 | halogen-substituted | 3 |
| 117 | hba1c-defined | 1 |
| 118 | hbv-related | 60 |
| 119 | hcv-induced | 8 |
| 120 | hcv-related | 57 |
| 121 | heat-shock-treated | 2 |
| 122 | hepatitis-related | 6 |
| 123 | hepatogenous | 4 |
| 124 | hepatotoxin-induced | 1 |
| 125 | high-mic | 6 |
| 126 | high/elevated | 2 |
| 127 | hirame | 1 |
| 128 | histopathology-verified | 1 |
| 129 | hnf1a | 9 |
| 130 | hoki | 1 |
| 131 | holter-detected | 2 |
| 132 | hospital-treated | 18 |
| 133 | htt-treated | 1 |
| 134 | igm-mgus | 11 |
| 135 | incident | 3,031 |
| 136 | incident/recurrent | 1 |
| 137 | indoline-2,3-diones | 1 |
| 138 | influenza-negative | 1 |
| 139 | insulin-dependand | 1 |
| 140 | insulin-dependent | 313 |
| 141 | insulin-requiring | 21 |
| 142 | insulinopenic | 3 |
| 143 | intertsil | 1 |
| 144 | interval-cancer | 1 |
| 145 | isio-4-fed | 1 |
| 146 | isoniazid-associated | 3 |
| 147 | jo2-induced | 4 |
| 148 | juvenile-onset | 25 |
| 149 | kazal | 2 |
| 150 | lamivudine-resistant | 26 |
| 151 | laparoscopically-proven | 1 |
| 152 | laser-refractory | 2 |
| 153 | late-onset | 383 |
| 154 | later-onset | 7 |
| 155 | less-controlled | 10 |
| 156 | lewy-body | 1 |
| 157 | lipoatrophy-associated | 1 |
| 158 | literacy-tailored | 1 |
| 159 | low-mic | 1 |
| 160 | low-substituted | 2 |
| 161 | lower-specificity | 1 |
| 162 | lvd-resistant | 2 |
| 163 | mat-adjacent | 1 |
| 164 | maturity-onset | 23 |
| 165 | mci/mild | 1 |
| 166 | medemine | 2 |
| 167 | medically-diagnosed | 1 |
| 168 | melancholic/non-melancholic | 1 |
| 169 | mets/no | 1 |
| 170 | mg/dl/no | 1 |
| 171 | miiand | 1 |
| 172 | mmr-deficient | 10 |
| 173 | moderate-to-high-risk | 2 |
| 174 | modified-process | 1 |
| 175 | msa-cerebellar | 1 |
| 176 | multi-infarct | 16 |
| 177 | nafld-associated | 3 |
| 178 | nathanson | 2 |
| 179 | nephrogenic | 37 |
| 180 | new-onset | 909 |
| 181 | newly-diagnosed | 59 |
| 182 | newonset | 1 |
| 183 | nkt-cell-dependent | 2 |
| 184 | nm-absorbing | 1 |
| 185 | non-b | 33 |
| 186 | non-biliogenic | 4 |
| 187 | non-c | 5 |
| 188 | non-cavitary | 5 |
| 189 | non-f | 7 |
| 190 | non-fatal/fatal | 1 |
| 191 | non-gbs | 2 |
| 192 | non-hemiplegic | 2 |
| 193 | non-i/r | 1 |
| 194 | non-insulin-dependence | 1 |
| 195 | non-insulin-dependent | 283 |
| 196 | non-intervened | 5 |
| 197 | non-mho | 2 |
| 198 | non-nodule | 2 |
| 199 | non-proteinuric | 16 |
| 200 | non-reentrant | 4 |
| 201 | non-ulcerative | 18 |
| 202 | noncarcinogenic | 13 |
| 203 | noninsulin-dependent | 34 |
| 204 | noninsulin-requiring | 3 |
| 205 | noninsulin-treated | 7 |
| 206 | nonneovascular | 3 |
| 207 | nonnephropathic | 1 |
| 208 | nonparanoid | 2 |
| 209 | nonresistant | 15 |
| 210 | nonsalvageable | 1 |
| 211 | nsclc-mediated | 1 |
| 212 | numeracy-focused | 1 |
| 213 | numeracy-sensitive | 1 |
| 214 | nurse/certified | 1 |
| 215 | obese- | 1 |
| 216 | officially-certified | 1 |
| 217 | one-hundred-eight | 1 |
| 218 | organically-based | 1 |
| 219 | overseas-acquired | 4 |
| 220 | pancreatogenic | 4 |
| 221 | participants.computer-based | 1 |
| 222 | pi-resistant | 2 |
| 223 | pioglitazone-for | 1 |
| 224 | pipkin | 8 |
| 225 | plaque-negative | 1 |
| 226 | plc-associated | 1 |
| 227 | poorly-controlled | 4 |
| 228 | post-cabg | 94 |
| 229 | post-ctr | 1 |
| 230 | post-hepatectomy | 4 |
| 231 | post-pneumonic | 1 |
| 232 | post-vitrectomy | 4 |
| 233 | postcabg | 2 |
| 234 | posthepatitic | 11 |
| 235 | postmenopausal-elderly | 1 |
| 236 | postpancreatitis | 2 |
| 237 | pre-ascitic | 3 |
| 238 | pre-gestational | 25 |
| 239 | pre-senile | 5 |
| 240 | pregestational | 72 |
| 241 | preretinopathic | 1 |
| 242 | presenile | 10 |
| 243 | prism-based | 2 |
| 244 | proinflammatory/anti-inflammatory | 1 |
| 245 | pseudo-resistant | 3 |
| 246 | ptz-and | 1 |
| 247 | quebracho/kg | 1 |
| 248 | re-creating | 1 |
| 249 | recent-onset | 157 |
| 250 | restrictive-purging | 1 |
| 251 | revascularizable | 2 |
| 252 | rsv-associated | 7 |
| 253 | ruboxistaurin-treated | 1 |
| 254 | sagb-alone | 1 |
| 255 | schistosoma-infected | 2 |
| 256 | screen-detected | 200 |
| 257 | senile | 249 |
| 258 | serially-admitted | 1 |
| 259 | serious/severe | 6 |
| 260 | sham-smt/control | 1 |
| 261 | siuds/sids | 1 |
| 262 | spermatozoa-positive | 1 |
| 263 | ssc-associated | 7 |
| 264 | stat3-wild | 1 |
| 265 | steroid-induced | 54 |
| 266 | streptozocin-induced | 3 |
| 267 | streptozotocin-induced | 115 |
| 268 | streptozotocin-nicotinamide-induced | 1 |
| 269 | streptozotocininduced | 1 |
| 270 | stz-induced | 100 |
| 271 | stz-na-induced | 2 |
| 272 | sub-optimally-controlled | 1 |
| 273 | subcompensated | 2 |
| 274 | supracardiac | 1 |
| 275 | taintless | 2 |
| 276 | thiazide-induced | 10 |
| 277 | trational | 1 |
| 278 | travel-associated | 3 |
| 279 | treatment-failure | 7 |
| 280 | trimesters.median | 1 |
| 281 | tubotympanic | 3 |
| 282 | tus-measured | 1 |
| 283 | type-1 | 210 |
| 284 | type-2 | 270 |
| 285 | type-ii | 48 |
| 286 | type1 | 9 |
| 287 | type2 | 9 |
| 288 | uti,4 | 1 |
| 289 | vascugel-treated | 1 |
| 290 | vh-derived | 4 |
| 291 | vtec-associated | 2 |
| 292 | weeks.serum | 1 |
| 293 | well-compensated | 13 |
| 294 | well-healed | 3 |
| 295 | xdr-pulmonary | 2 |
| 296 | young-onset | 11 |
| 297 | youth-onset | 6 |
| 298 | ypt0-2 | 5 |
| 1 | all+++ | 1 |
| 2 | all++ | 1 |
| 3 | all+ | 1 |
| 4 | obese- | 1 |
| 5 | 117,000 | 1 |
| 6 | 36,600 | 1 |
| 7 | 9,710 | 1 |
| 8 | 1,420 | 3 |
| 9 | 3,430 | 2 |
| 10 | 9340 | 3 |
| 11 | 7,490 | 1 |
| 12 | type-1 | 210 |
| 13 | 5811 | 1 |
| 14 | 58/61 | 1 |
| 15 | type1 | 9 |
| 16 | class1 | 6 |
| 17 | ypt0-2 | 5 |
| 18 | type-2 | 270 |
| 19 | 13,102 | 2 |
| 20 | 10,722 | 1 |
| 21 | 4932 | 1 |
| 22 | 7,252 | 1 |
| 23 | 29,452 | 1 |
| 24 | 58,162 | 1 |
| 25 | 3,492 | 1 |
| 26 | 49/592 | 1 |
| 27 | type2 | 9 |
| 28 | genotype-3 | 4 |
| 29 | 17,213 | 1 |
| 30 | 8d3 | 1 |
| 31 | g2/g3 | 4 |
| 32 | uti,4 | 1 |
| 33 | 285.4 | 1 |
| 34 | 6214 | 2 |
| 35 | 37,514 | 1 |
| 36 | 504,844 | 1 |
| 37 | 16,254 | 1 |
| 38 | 97,854 | 1 |
| 39 | 19,864 | 1 |
| 40 | 12,835 | 1 |
| 41 | 86,075 | 1 |
| 42 | 4,606 | 1 |
| 43 | 14,806 | 1 |
| 44 | 8,226 | 1 |
| 45 | 94256 | 1 |
| 46 | 5,076 | 1 |
| 47 | 20,586 | 1 |
| 48 | 24,937 | 1 |
| 49 | 5647 | 2 |
| 50 | 962-1757 | 1 |
| 51 | 3,548 | 1 |
| 52 | 3,748 | 1 |
| 53 | 620,478 | 1 |
| 54 | 5,009 | 1 |
| 55 | 19,909 | 1 |
| 56 | 816,149 | 1 |
| 57 | 1,744,659 | 1 |
| 58 | 25,759 | 1 |
| 59 | 15,859 | 1 |
| 60 | 150,389 | 1 |
| 61 | hnf1a | 9 |
| 62 | non-b | 33 |
| 63 | drug-resistant-mtb | 1 |
| 64 | non-c | 5 |
| 65 | supracardiac | 1 |
| 66 | amebic | 17 |
| 67 | non-hemiplegic | 2 |
| 68 | preretinopathic | 1 |
| 69 | nonnephropathic | 1 |
| 70 | melancholic/non-melancholic | 1 |
| 71 | alcoholic | 1,084 |
| 72 | high-mic | 6 |
| 73 | low-mic | 1 |
| 74 | tubotympanic | 3 |
| 75 | non-biliogenic | 4 |
| 76 | noncarcinogenic | 13 |
| 77 | nephrogenic | 37 |
| 78 | pancreatogenic | 4 |
| 79 | insulinopenic | 3 |
| 80 | post-pneumonic | 1 |
| 81 | carcinogens-chronic | 1 |
| 82 | non-proteinuric | 16 |
| 83 | cholestatic | 156 |
| 84 | pre-ascitic | 3 |
| 85 | arteritic | 6 |
| 86 | ectoparasitic | 10 |
| 87 | posthepatitic | 11 |
| 88 | jo2-induced | 4 |
| 89 | stz-na-induced | 2 |
| 90 | steroid-induced | 54 |
| 91 | streptozotocin-nicotinamide-induced | 1 |
| 92 | thiazide-induced | 10 |
| 93 | alloxan-induced | 46 |
| 94 | streptozotocin-induced | 115 |
| 95 | streptozocin-induced | 3 |
| 96 | hepatotoxin-induced | 1 |
| 97 | hcv-induced | 8 |
| 98 | benfluorex-induced | 1 |
| 99 | stz-induced | 100 |
| 100 | streptozotocininduced | 1 |
| 101 | isio-4-fed | 1 |
| 102 | ch-fed | 4 |
| 103 | histopathology-verified | 1 |
| 104 | officially-certified | 1 |
| 105 | nurse/certified | 1 |
| 106 | well-healed | 3 |
| 107 | less-controlled | 10 |
| 108 | sub-optimally-controlled | 1 |
| 109 | poorly-controlled | 4 |
| 110 | non-intervened | 5 |
| 111 | hba1c-defined | 1 |
| 112 | glucose-defined | 1 |
| 113 | overseas-acquired | 4 |
| 114 | literacy-tailored | 1 |
| 115 | tus-measured | 1 |
| 116 | prism-based | 2 |
| 117 | participants.computer-based | 1 |
| 118 | organically-based | 1 |
| 119 | medically-diagnosed | 1 |
| 120 | newly-diagnosed | 59 |
| 121 | numeracy-focused | 1 |
| 122 | crt-d-treated | 2 |
| 123 | fomepizole-treated | 4 |
| 124 | ginseng-treated | 1 |
| 125 | heat-shock-treated | 2 |
| 126 | hospital-treated | 18 |
| 127 | vascugel-treated | 1 |
| 128 | alloxan-treated | 3 |
| 129 | noninsulin-treated | 7 |
| 130 | ruboxistaurin-treated | 1 |
| 131 | glp-treated | 3 |
| 132 | bionator-treated | 1 |
| 133 | htt-treated | 1 |
| 134 | bpiv3-associated | 1 |
| 135 | vtec-associated | 2 |
| 136 | plc-associated | 1 |
| 137 | ssc-associated | 7 |
| 138 | isoniazid-associated | 3 |
| 139 | nafld-associated | 3 |
| 140 | travel-associated | 3 |
| 141 | rsv-associated | 7 |
| 142 | lipoatrophy-associated | 1 |
| 143 | nsclc-mediated | 1 |
| 144 | atheroma-related | 1 |
| 145 | hepatitis-related | 6 |
| 146 | hbv-related | 60 |
| 147 | hcv-related | 57 |
| 148 | de-compensated | 2 |
| 149 | well-compensated | 13 |
| 150 | subcompensated | 2 |
| 151 | haemolysis-elevated | 1 |
| 152 | high/elevated | 2 |
| 153 | cancer-unaffected | 2 |
| 154 | schistosoma-infected | 2 |
| 155 | clinically-suspected | 3 |
| 156 | screen-detected | 200 |
| 157 | holter-detected | 2 |
| 158 | biopsy-documented | 1 |
| 159 | serially-admitted | 1 |
| 160 | halogen-substituted | 3 |
| 161 | 4-n-alkylamino-substituted | 1 |
| 162 | low-substituted | 2 |
| 163 | vh-derived | 4 |
| 164 | central-involved | 1 |
| 165 | center-involved | 11 |
| 166 | challenge-proved | 1 |
| 167 | nonparanoid | 2 |
| 168 | mci/mild | 1 |
| 169 | stat3-wild | 1 |
| 170 | ptz-and | 1 |
| 171 | insulin-dependand | 1 |
| 172 | miiand | 1 |
| 173 | non-insulin-dependence | 1 |
| 174 | nonsalvageable | 1 |
| 175 | revascularizable | 2 |
| 176 | bari-eligible | 1 |
| 177 | drug-susceptible | 29 |
| 178 | senile | 249 |
| 179 | pre-senile | 5 |
| 180 | presenile | 10 |
| 181 | non-nodule | 2 |
| 182 | hirame | 1 |
| 183 | medemine | 2 |
| 184 | sagb-alone | 1 |
| 185 | all-type | 14 |
| 186 | serious/severe | 6 |
| 187 | treatment-failure | 7 |
| 188 | early-course | 12 |
| 189 | influenza-negative | 1 |
| 190 | plaque-negative | 1 |
| 191 | ebv-negative | 4 |
| 192 | biopsy-negative | 8 |
| 193 | non-ulcerative | 18 |
| 194 | drug-sensitive | 47 |
| 195 | numeracy-sensitive | 1 |
| 196 | spermatozoa-positive | 1 |
| 197 | ebv-positive | 29 |
| 198 | non-f | 7 |
| 199 | post-cabg | 94 |
| 200 | postcabg | 2 |
| 201 | quebracho/kg | 1 |
| 202 | nm-absorbing | 1 |
| 203 | co-managing | 2 |
| 204 | restrictive-purging | 1 |
| 205 | food-poisoning | 1 |
| 206 | insulin-requiring | 21 |
| 207 | noninsulin-requiring | 3 |
| 208 | re-creating | 1 |
| 209 | amelorating | 1 |
| 210 | an-restricting | 1 |
| 211 | center-involving | 8 |
| 212 | type-ii | 48 |
| 213 | hoki | 1 |
| 214 | frank | 138 |
| 215 | moderate-to-high-risk | 2 |
| 216 | bilineal | 2 |
| 217 | trational | 1 |
| 218 | pre-gestational | 25 |
| 219 | pregestational | 72 |
| 220 | non-fatal/fatal | 1 |
| 221 | kazal | 2 |
| 222 | intertsil | 1 |
| 223 | sham-smt/control | 1 |
| 224 | efthidermum | 1 |
| 225 | weeks.serum | 1 |
| 226 | trimesters.median | 1 |
| 227 | laparoscopically-proven | 1 |
| 228 | pipkin | 8 |
| 229 | bone/skin | 1 |
| 230 | nathanson | 2 |
| 231 | non-mho | 2 |
| 232 | mg/dl/no | 1 |
| 233 | mets/no | 1 |
| 234 | crown-group | 2 |
| 235 | non-i/r | 1 |
| 236 | daily-wear | 2 |
| 237 | msa-cerebellar | 1 |
| 238 | nonneovascular | 3 |
| 239 | interval-cancer | 1 |
| 240 | pioglitazone-for | 1 |
| 241 | post-ctr | 1 |
| 242 | non-gbs | 2 |
| 243 | siuds/sids | 1 |
| 244 | indoline-2,3-diones | 1 |
| 245 | postpancreatitis | 2 |
| 246 | modified-process | 1 |
| 247 | taintless | 2 |
| 248 | igm-mgus | 11 |
| 249 | ethnically-homogeneous | 1 |
| 250 | hepatogenous | 4 |
| 251 | 27884=cect | 1 |
| 252 | multi-infarct | 16 |
| 253 | childhood-onset | 69 |
| 254 | juvenile-onset | 25 |
| 255 | late-onset | 383 |
| 256 | young-onset | 11 |
| 257 | youth-onset | 6 |
| 258 | gestational-onset | 6 |
| 259 | later-onset | 7 |
| 260 | adult-onset | 110 |
| 261 | recent-onset | 157 |
| 262 | new-onset | 909 |
| 263 | early-onset | 525 |
| 264 | maturity-onset | 23 |
| 265 | newonset | 1 |
| 266 | dual-graft | 1 |
| 267 | one-hundred-eight | 1 |
| 268 | non-reentrant | 4 |
| 269 | lvd-resistant | 2 |
| 270 | ciprofloxacin-imipenem-trimethoprim/sulfamethoxazole-resistant | 1 |
| 271 | lamivudine-resistant | 26 |
| 272 | drug-resistant | 511 |
| 273 | h-resistant | 2 |
| 274 | pi-resistant | 2 |
| 275 | pseudo-resistant | 3 |
| 276 | nonresistant | 15 |
| 277 | mat-adjacent | 1 |
| 278 | incident | 3,031 |
| 279 | nkt-cell-dependent | 2 |
| 280 | insulin-dependent | 313 |
| 281 | non-insulin-dependent | 283 |
| 282 | noninsulin-dependent | 34 |
| 283 | mmr-deficient | 10 |
| 284 | incident/recurrent | 1 |
| 285 | 'breakfast | 1 |
| 286 | burnt-out | 1 |
| 287 | lewy-body | 1 |
| 288 | acute/early | 3 |
| 289 | postmenopausal-elderly | 1 |
| 290 | post-vitrectomy | 4 |
| 291 | post-hepatectomy | 4 |
| 292 | xdr-pulmonary | 2 |
| 293 | non-cavitary | 5 |
| 294 | proinflammatory/anti-inflammatory | 1 |
| 295 | drug-refractory | 53 |
| 296 | laser-refractory | 2 |
| 297 | lower-specificity | 1 |
| 298 | evidence.• | 13 |